Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis

Cell Research

Volumn 24, Issue 10, 2014, Pages 1214-1230

  Yu, Tao ^a   Tao, Yonghui ^a   Yang, Meiqiang ^a   Chen, Peng ^a   Gao, Xiaobo ^a   Zhang, Yanbo ^a,b   Zhang, Tao ^c   Chen, Zi ^c   Hou, Jian ^d   Zhang, Yan ^b   Ruan, Kangcheng ^a   Wang, Hongyan ^b   Hu, Ronggui ^a,b  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b Chinese Academy of Sciences   (China)

^c FUDAN UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

bortezomib; combination therapy; N end rule; proteasome homeostasis; protein degradome; proteostasis; ubiquitin

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; ONCOPROTEIN; PHOTOPROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PSMD10 PROTEIN, HUMAN; PYRAZINE DERIVATIVE; TRANSCRIPTOME;

APOPTOSIS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE LIBRARY; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION;

APOPTOSIS; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; GENE LIBRARY; HEK293 CELLS; HUMANS; LUMINESCENT PROTEINS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN ARRAY ANALYSIS; PROTEIN INTERACTION MAPS; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS; PYRAZINES; TRANSCRIPTOME;

EID: 84926181557     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2014.122     Document Type: Article

References (72)

1. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486:537-540.
2. Soon WW, Hariharan M, Snyder MP. High-throughput sequencing for biology and medicine. Mol Syst Biol 2013; 9:640.
3. Wacker SA, Houghtaling BR, Elemento O, Kapoor TM. Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat Chem Biol 2012; 8:235-237.
4. Vabulas RM, Hartl FU. Protein synthesis upon acute nutrient restriction relies on proteasome function. Science 2005; 310:1960-1963.
5. Finley D, Ciechanover A, Varshavsky A. Ubiquitin as a central cellular regulator. Cell 2004; 116:S29-S32.
6. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67:425-479.
7. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78:959-991.
8. Haendler B, Jentsch S. The ubiquitin system in health and disease. Preface. Ernst Schering Found Symp Proc 2008; 1:VVI.
9. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009; 458:438-444.
10. Ang XL, Harper JW. A road map of cellular protein homeostasis. Nat Chem Biol 2009; 5:9-11.
11. Yen HC, Xu Q, Chou DM, Zhao Z, Elledge SJ. Global protein stability profiling in mammalian cells. Science 2008; 322:918-923.
12. Yewdell JW, Lacsina JR, Rechsteiner MC, Nicchitta CV. Out with the old, in with the new? Comparing methods for measuring protein degradation. Cell Biol Int 2011; 35:457-462.
13. Shaner NC, Steinbach PA, Tsien RY. A guide to choosing fluorescent proteins. Nat Methods 2005; 2:905-909.
14. Emanuele MJ, Elia AE, Xu Q, et al. Global identification of modular cullin-RING ligase substrates. Cell 2011; 147:459-474.
15. Khmelinskii A, Keller PJ, Bartosik A, et al. Tandem fluorescent protein timers for in vivo analysis of protein dynamics. Nat Biotechnol 2012; 30:708-714.
16. Komar AA, Hatzoglou M. Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. Cell Cycle 2011; 10:229-240.
17. Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl 2005; 44:7342-7372.
18. Piatkov KI, Brower CS, Varshavsky A. The N-end rule pathway counteracts cell death by destroying proapoptotic protein fragments. Proc Natl Acad Sci USA 2012; 109:E1839-E1847.
19. Varshavsky A. The N-end rule pathway and regulation by proteolysis. Protein Sci 2011; 20:1298-1345.
20. Tasaki T, Sriram SM, Park KS, Kwon YT. The N-end rule pathway. Annual Rev Biochem 2012; 81:261-289.
21. Varshavsky A. Three decades of studies to understand the functions of the ubiquitin family. Methods Mol Biol 2012; 832:1-11.
22. Verma R, Oania RS, Kolawa NJ, Deshaies RJ. Cdc48/p97 promotes degradation of aberrant nascent polypeptides bound to the ribosome. Elife 2013; 2:e00308.
23. Turner GC, Varshavsky A. Detecting and measuring cotranslational protein degradation in vivo. Science 2000; 289:2117-2120.
24. Brower CS, Piatkov KI, Varshavsky A. Neurodegeneration-associated protein fragments as short-lived substrates of the N-end rule pathway. Mol Cell 2013; 50:161-171.
25. Hwang CS, Varshavsky A. Regulation of peptide import through phosphorylation of Ubr1, the ubiquitin ligase of the N-end rule pathway. Proc Natl Acad Sci USA 2008; 105:19188-19193.
26. Goldberg AL. Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol 2012; 199:583-588.
27. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011; 11:239-253.
28. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
29. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116:679-686.
30. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011; 103:1007-1017.
31. Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 1986; 234:179-186.
32. Varshavsky A. Ubiquitin fusion technique and related methods. Methods Enzymol 2005; 399:777-799.
33. Shimoji T, Murakami K, Sugiyama Y, et al. Identification of annexin A1 as a novel substrate for E6AP-mediated ubiquitylation. J Cell Biochem 2009; 106:1123-1135.
34. Hu RG, Sheng J, Qi X, Xu Z, Takahashi TT, Varshavsky A. The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators. Nature 2005; 437:981-986.
35. An JY, Seo JW, Tasaki T, Lee MJ, Varshavsky A, Kwon YT. Impaired neurogenesis and cardiovascular development in mice lacking the E3 ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway. Proc Natl Acad Sci USA 2006; 103:6212-6217.
36. Lee PC, Sowa ME, Gygi SP, Harper JW. Alternative ubiquitin activation/conjugation cascades interact with N-end rule ubiquitin ligases to control degradation of RGS proteins. Mol Cell 2011; 43:392-405.
37. Rual JF, Hirozane-Kishikawa T, Hao T, et al. Human ORFeome version 1.1: a platform for reverse proteomics. Genome Res 2004; 14:2128-2135.
38. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4:P3.
39. Thomas PD, Kejariwal A, Campbell MJ, et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003; 31:334-341.
40. Bader GD, Cary MP, Sander C. Pathguide: a pathway resource list. Nucleic Acids Res 2006; 34:D504-D506.
41. Lioni M, Noma K, Snyder A, et al. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther 2008; 7:2866-2875.
42. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91:3-21.
43. Oyajobi BO, Garrett IR, Gupta A, et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007; 139:434-438.
44. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
45. Deberardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 2012; 148:1132-1144.
46. Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004; 5:101-113.
47. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011; 39:D561-D568.
48. Hou J, Lin FY, Zhang B, Zhang LZ, Ding SQ. Establishment and biological characteristics of human multiple myeloma cell line CZ-1. Chin Med J (Engl) 2004; 117:115-119.
49. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7:763-777.
50. Hanna J, Meides A, Zhang DP, Finley D. A ubiquitin stress response induces altered proteasome composition. Cell 2007; 129:747-759.
51. Aiken CT, Kaake RM, Wang X, Huang L. Oxidative stress-mediated regulation of proteasome complexes. Mol Cell Proteomics 2011; 10:R110.006924.
52. Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, Deshaies RJ. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell 2010; 38:17-28.
53. Kwak MK, Kensler TW. Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway. Biochem Biophys Res Commun 2006; 345:1350-1357.
54. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008; 112:2489-2499.
55. Lichter DI, Danaee H, Pickard MD, et al. Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood 2012; 120:4513-4516.
56. Tomko RJ Jr, Funakoshi M, Schneider K, Wang J, Hochstrasser M. Heterohexameric ring arrangement of the eukaryotic proteasomal ATPases: implications for proteasome structure and assembly. Mol Cell 2010; 38:393-403.
57. Xie Y. Structure, assembly and homeostatic regulation of the 26S proteasome. J Mol Cell Biol 2010; 2:308-317.
58. Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 2008; 9:679-690.
59. Geng F, Wenzel S, Tansey WP. Ubiquitin and proteasomes in transcription. Annu Rev Biochem 2012; 81:177-201.
60. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107:4907-4916.
61. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334:297-314.
62. Yao Z, Fenoglio S, Gao DC, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 2010; 107:15535-15540.
63. Kuhn M, Szklarczyk D, Franceschini A, et al. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res 2010; 38:D552-D556.
64. Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005; 65:3828-3836.
65. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11:515-528.
66. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
67. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008; 9:387-402.
68. Schlachter C, Lisdat F, Frohme M, et al. Pushing the detection limits: the evanescent field in surface plasmon resonance and analyte-induced folding observation of long human telomeric repeats. Biosens Bioelectron 2012; 31:571-574.
69. Conze D, Weiss L, Regen PS, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001; 61:8851-8858.
70. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2010; 115:834-845.
71. Alberti S, Gitler AD, Lindquist S. A suite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast 2007; 24:913-919.
72. Lamesch P, Li N, Milstein S, et al. hORFeome v3.1: a resource of human open reading frames representing over 10 000 human genes. Genomics 2007; 89:307-315.